A separate study demonstrated that dual blockade of c-Met with SU11274 and EGFR with erlotinib in erlotinib-sensitive HNSCC cell lines decreased viability significantly more than exposure to either single agent, and these agents acted synergistically [41]. Here, MET is linked to head and neck squamous cell carcinoma.